Comparison 8. n‐3 LCPUFA supplementation versus placebo or no supplementation ‐ sensitivity analysis.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Any allergies (with sensitisation): medically diagnosed IgE mediated	1		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
1.1 12 to 36 months	1	706	Risk Ratio (M‐H, Fixed, 95% CI)	0.68 [0.44, 1.05]
1.2 Beyond 36 months	1	706	Risk Ratio (M‐H, Fixed, 95% CI)	0.86 [0.61, 1.20]
2 Any allergies (+/‐ sensitisation): medically diagnosed/parental reported	2		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
2.1 12 to 36 months	1	706	Risk Ratio (M‐H, Fixed, 95% CI)	0.91 [0.71, 1.16]
2.2 Beyond 36 months	2	1237	Risk Ratio (M‐H, Fixed, 95% CI)	0.98 [0.86, 1.12]